Trusted Resources: News & Meetings
Latest announcements and gatherings
Horizon Therapeutics Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application for Active Thyroid Eye Disease Treatment
Horizon Therapeutics plc today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for teprotumumab, an investigational medicine for the treatment of active thyroid eye disease (TED), and granted it Priority Review designation. The FDA grants Priority Review designation to applications for medicines that have the potential to provide significant improvements in the treatment of serious conditions. Priority Review is associated with an accelerated six-month review period compared to the standard ten-month review period. If approved, teprotumumab would be the first FDA-approved medicine for the treatment of active TED.
“Priority Review for the teprotumumab BLA is another positive step toward our goal to make a difference in the lives of people who are living with active TED – a painful, debilitating and vision-threatening rare disease,” said Timothy Walbert, Chairman, President and Chief Executive Officer, Horizon.
myBinderRelated Content
-
Orbital Pain – Dr. Raymond Douglashttps://www.youtube.com/watch?v=qHqEGxMr...
-
Ask a Doctor questions about Graves’ disease, thyroid eye disease, & Hashimoto’s thyroiditishttps://www.youtube.com/watch?v=RxElrnS6...
-
Swaraj Bose, MDDr. Swaraj Bose was an Associate Profess...
-
Catherine J. Hwang, MDDr. Catherine J. Hwang was born in New Y...
-
Graves’ OrbitopathyEpidemiology: Eye complications occur i...
-
Prospective, Systematically Recorded Mycophenolate Safety Data in Graves’ OrbitopathyContext: The antiproliferative mechanis...
-
Diagnosis and Management of Graves Disease – David Cooper, MDEdward H. Livingston, MD discusses Grave...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Facebook
Google